Boston Scientific Corporation
NYSE:BSX · New York Stock Exchange
+$0.45 today
Vol 30.83M · Avg 19.45M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $2.9B +56.7% | $1.8B +16.0% | $1.6B +128.1% | $698.0M -32.9% | $1.0B | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.4B +7.8% | $1.3B +6.1% | $1.2B +5.3% | $1.1B +3.9% | $1.1B | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$2.0M +97.1% | -$70.0M -6900.0% | -$1.0M +98.4% | -$63.0M +49.2% | -$124.0M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $299.0M +12.4% | $266.0M +14.2% | $233.0M +5.9% | $220.0M +13.4% | $194.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$246.0M +46.8% | -$462.0M +40.0% | -$770.0M +23.4% | -$1.0B -186.3% | -$351.0M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$269.0M +23.4% | -$351.0M -47.5% | -$238.0M -8.2% | -$220.0M +21.1% | -$279.0M | $592.6M | $1.3B | $626.2M |
| Inventory | -$188.0M +17.5% | -$228.0M +65.5% | -$660.0M -105.6% | -$321.0M +7.2% | -$346.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $296.0M +21.8% | $243.0M +105.9% | $118.0M +146.3% | -$255.0M -162.5% | $408.0M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$85.0M +32.5% | -$126.0M -1360.0% | $10.0M +104.8% | -$209.0M -56.0% | -$134.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $223.0M -61.9% | $586.0M +131.6% | $253.0M -53.1% | $540.0M +2900.0% | $18.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $4.5B +32.0% | $3.4B +37.2% | $2.5B +64.0% | $1.5B -18.4% | $1.9B | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$876.0M -10.9% | -$790.0M +1.3% | -$800.0M -30.7% | -$612.0M -10.5% | -$554.0M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$1.6B +65.7% | -$4.6B -156.2% | -$1.8B -17.8% | -$1.5B -7.3% | -$1.4B | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 +100.0% | -$24.0M -125.0% | $96.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 -100.0% | $56.0M -81.0% | $294.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$171.0M +33.5% | -$257.0M -394.2% | -$52.0M -149.1% | $106.0M +10700.0% | -$1.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$2.6B +53.6% | -$5.7B -120.9% | -$2.6B -28.0% | -$2.0B -25.9% | -$1.6B | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$491.0M -126.9% | $1.8B +45775.0% | -$4.0M +97.6% | -$165.0M | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $282.0M +22.6% | $230.0M +26.4% | $182.0M | $0 -100.0% | $110.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 -100.0% | $136.0M | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 +100.0% | -$28.0M +49.1% | -$55.0M +0.0% | -$55.0M | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$186.0M +23.5% | -$243.0M -67.6% | -$145.0M +68.8% | -$464.0M -209.3% | -$150.0M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$395.0M -121.8% | $1.8B +36180.0% | $5.0M +100.9% | -$548.0M -476.8% | -$95.0M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $42.0M +481.8% | -$11.0M +31.3% | -$16.0M -77.8% | -$9.0M -12.5% | -$8.0M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $1.5B +443.2% | -$449.0M -447.6% | -$82.0M +92.1% | -$1.0B -709.4% | $171.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $3.7B +38.3% | $2.6B +55.3% | $1.7B +86.3% | $914.0M -30.5% | $1.3B | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$181.01B
Abbott Laboratories
NYSE:ABT
$153.82B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.65B
Pfizer Inc.
NYSE:PFE
$144.22B
Danaher Corporation
NYSE:DHR
$126.07B
Stryker Corporation
NYSE:SYK
$119.35B
Medtronic plc
NYSE:MDT
$101.66B
Sanofi
NASDAQ:SNY
$101.44B
McKesson Corporation
NYSE:MCK
$87.60B
HCA Healthcare, Inc.
NYSE:HCA
$83.16B
SEC Filings
Recent regulatory filings
No filings found.
Does BSX generate free cash flow?
Boston Scientific Corporation (BSX) generated $3.66B of free cash flow in fiscal 2025.
How much operating cash flow does BSX produce?
Operating cash flow was $4.53B, before capital expenditures of $876.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.